{"id":37417,"date":"2025-07-16T15:19:20","date_gmt":"2025-07-16T07:19:20","guid":{"rendered":"https:\/\/flcube.com\/?p=37417"},"modified":"2025-07-16T15:19:20","modified_gmt":"2025-07-16T07:19:20","slug":"xgene-licenses-novel-non-opioid-analgesic-xg005-to-neurogen-for-greater-china-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37417","title":{"rendered":"Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development"},"content":{"rendered":"\n<p>Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care specialist established in late 2024 following the acquisition of UCB&#8217;s mature neurology and allergy business in China by CBC Group and Mubadala Investment Company. Under the agreement, NeuroGen secures exclusive rights for the development, registration, production, and commercialization of Xgene&#8217;s novel non-opioid analgesic, XG005, in Mainland China, Hong Kong, and Macau. Xgene retains global rights outside these territories.<\/p>\n\n\n\n<p><strong>Financial Terms<\/strong><br>Xgene will receive an undisclosed upfront payment, along with development and sales milestone payments, and tiered royalties on net sales. This strategic partnership leverages NeuroGen&#8217;s expertise in neurology and Xgene&#8217;s innovative drug development capabilities.<\/p>\n\n\n\n<p><strong>XG005: Dual Analgesic Mechanism<\/strong><br>XG005 demonstrates dual analgesic mechanisms through cyclooxygenase (COX) inhibition and peripheral \u03b12\u03b4 calcium channel modulation. It is being developed for inflammatory and neuropathic pain indications. Positive results have been observed in the U.S. Phase II\/III bunionectomy study and China Phase IIb osteoarthritis trial. An additional Phase III trial for abdominal surgery pain is planned in the U.S. in 2025, with a New Drug Application (NDA) submission to follow.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/Xgene-and-NeuroGen-Enter-into-Exclusive-License-Agreement-for-XG005.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Xgene-and-NeuroGen-Enter-into-Exclusive-License-Agreement-for-XG005.\"><\/object><a id=\"wp-block-file--media-fc18193e-f995-463a-be29-346fb77be3d5\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/Xgene-and-NeuroGen-Enter-into-Exclusive-License-Agreement-for-XG005.pdf\">Xgene-and-NeuroGen-Enter-into-Exclusive-License-Agreement-for-XG005<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/Xgene-and-NeuroGen-Enter-into-Exclusive-License-Agreement-for-XG005.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fc18193e-f995-463a-be29-346fb77be3d5\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37420,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,4226,131,4225],"class_list":["post-37417","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-neurogen-pharma","tag-ucb","tag-xgene-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care specialist established in late 2024 following the acquisition of UCB&#039;s mature neurology and allergy business in China by CBC Group and Mubadala Investment Company. Under the agreement, NeuroGen secures exclusive rights for the development, registration, production, and commercialization of Xgene&#039;s novel non-opioid analgesic, XG005, in Mainland China, Hong Kong, and Macau. Xgene retains global rights outside these territories.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37417\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development\" \/>\n<meta property=\"og:description\" content=\"Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care specialist established in late 2024 following the acquisition of UCB&#039;s mature neurology and allergy business in China by CBC Group and Mubadala Investment Company. Under the agreement, NeuroGen secures exclusive rights for the development, registration, production, and commercialization of Xgene&#039;s novel non-opioid analgesic, XG005, in Mainland China, Hong Kong, and Macau. Xgene retains global rights outside these territories.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37417\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-16T07:19:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37417#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37417\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development\",\"datePublished\":\"2025-07-16T07:19:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37417\"},\"wordCount\":203,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37417#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1602.webp\",\"keywords\":[\"Biotech\",\"NeuroGen Pharma\",\"UCB\",\"Xgene Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37417#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37417\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37417\",\"name\":\"Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37417#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37417#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1602.webp\",\"datePublished\":\"2025-07-16T07:19:20+00:00\",\"description\":\"Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care specialist established in late 2024 following the acquisition of UCB's mature neurology and allergy business in China by CBC Group and Mubadala Investment Company. Under the agreement, NeuroGen secures exclusive rights for the development, registration, production, and commercialization of Xgene's novel non-opioid analgesic, XG005, in Mainland China, Hong Kong, and Macau. Xgene retains global rights outside these territories.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37417#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37417\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37417#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1602.webp\",\"width\":1080,\"height\":608,\"caption\":\"Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37417#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care specialist established in late 2024 following the acquisition of UCB's mature neurology and allergy business in China by CBC Group and Mubadala Investment Company. Under the agreement, NeuroGen secures exclusive rights for the development, registration, production, and commercialization of Xgene's novel non-opioid analgesic, XG005, in Mainland China, Hong Kong, and Macau. Xgene retains global rights outside these territories.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37417","og_locale":"en_US","og_type":"article","og_title":"Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development","og_description":"Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care specialist established in late 2024 following the acquisition of UCB's mature neurology and allergy business in China by CBC Group and Mubadala Investment Company. Under the agreement, NeuroGen secures exclusive rights for the development, registration, production, and commercialization of Xgene's novel non-opioid analgesic, XG005, in Mainland China, Hong Kong, and Macau. Xgene retains global rights outside these territories.","og_url":"https:\/\/flcube.com\/?p=37417","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-16T07:19:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37417#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37417"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development","datePublished":"2025-07-16T07:19:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37417"},"wordCount":203,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37417#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1602.webp","keywords":["Biotech","NeuroGen Pharma","UCB","Xgene Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37417#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37417","url":"https:\/\/flcube.com\/?p=37417","name":"Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37417#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37417#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1602.webp","datePublished":"2025-07-16T07:19:20+00:00","description":"Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care specialist established in late 2024 following the acquisition of UCB's mature neurology and allergy business in China by CBC Group and Mubadala Investment Company. Under the agreement, NeuroGen secures exclusive rights for the development, registration, production, and commercialization of Xgene's novel non-opioid analgesic, XG005, in Mainland China, Hong Kong, and Macau. Xgene retains global rights outside these territories.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37417#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37417"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37417#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1602.webp","width":1080,"height":608,"caption":"Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37417#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1602.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37417"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37417\/revisions"}],"predecessor-version":[{"id":37421,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37417\/revisions\/37421"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37420"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}